Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary - About
Organon & Co (OGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: OGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -4.12% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.04B USD | Price to earnings Ratio 4.71 | 1Y Target Price 20.5 |
Price to earnings Ratio 4.71 | 1Y Target Price 20.5 | ||
Volume (30-day avg) 2829346 | Beta 0.72 | 52 Weeks Range 13.87 - 22.70 | Updated Date 02/21/2025 |
52 Weeks Range 13.87 - 22.70 | Updated Date 02/21/2025 | ||
Dividends yield (FY) 7.33% | Basic EPS (TTM) 3.33 |
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-13 | When Before Market | Estimate 0.8658 | Actual 0.9 |
Profitability
Profit Margin 13.49% | Operating Margin (TTM) 21.48% |
Management Effectiveness
Return on Assets (TTM) 7.91% | Return on Equity (TTM) 40.85% |
Valuation
Trailing PE 4.71 | Forward PE 5.03 | Enterprise Value 11923769398 | Price to Sales(TTM) 0.63 |
Enterprise Value 11923769398 | Price to Sales(TTM) 0.63 | ||
Enterprise Value to Revenue 1.86 | Enterprise Value to EBITDA 8.99 | Shares Outstanding 257539008 | Shares Floating 256717326 |
Shares Outstanding 257539008 | Shares Floating 256717326 | ||
Percent Insiders 0.29 | Percent Institutions 84.03 |
AI Summary
Organon & Co. (OGN): A Comprehensive Stock Overview
Company Profile
History and Background:
Organon & Co. (OGN) was spun off from Merck & Co. in June 2021. Merck retains a 19.9% ownership stake in Organon. With a history dating back to 1917, Organon boasts a rich heritage in women's health and biosimilars. This heritage forms the foundation for the company's current core business areas.
Core Business Areas:
- Women's Health: Focuses on contraception, fertility, and menopause solutions, including well-known brands like NuvaRing and Nexplanon.
- Biosimilars: Develops and commercializes biosimilar versions of leading biologic drugs, offering affordable alternatives to patients.
- Established Brands: Markets other established medications in areas like cardiovascular and pain management.
Leadership and Corporate Structure:
- CEO: Kevin Ali
- CFO: Matt Walsh
- President: Peter Guenter
- Headquartered in Jersey City, US
- Operates in over 150 markets
Top Products and Market Share
Top Products:
- NuvaRing: A combined hormonal contraceptive vaginal ring.
- Nexplanon: A single-rod contraceptive implant.
- Repatha: A PCSK9 inhibitor for reducing LDL cholesterol.
- Olumiant: A JAK inhibitor for treating rheumatoid arthritis and other autoimmune diseases.
Market Share:
- NuvaRing: Global leader in the combined hormonal contraceptive vaginal ring market.
- Nexplanon: Market leader in the contraceptive implant market in the US and Europe.
- Repatha: Holds a significant share in the PCSK9 inhibitor market.
- Olumiant: Growing market share in the JAK inhibitor market for rheumatoid arthritis.
Product Performance and Competitor Comparison:
- Organon's top products hold leading positions in their respective markets, reflecting their strong performance and brand recognition.
- The company faces competition from major pharmaceutical players in each of its business areas.
- Women's Health: Main competitors include Bayer, Pfizer, and Teva.
- Biosimilars: Competes with established players like Sandoz, Amgen, and Samsung Bioepis.
- Established Brands: Competes with various generic and branded drug companies.
Total Addressable Market
The total addressable market (TAM) for Organon is vast, encompassing:
- Women's health: Estimated at over $30 billion globally.
- Biosimilars: Expected to reach $80 billion by 2025.
- Cardiovascular and pain management: Billion-dollar markets with significant growth potential.
Financial Performance
Recent Financial Statements:
- Revenue: $6.4 billion in 2022, up 7% year-over-year.
- Net Income: $1.1 billion in 2022, down 15% year-over-year.
- Profit Margin: 16.8% in 2022.
- Earnings per Share (EPS): $4.44 in 2022.
Cash Flow and Balance Sheet:
- Strong cash flow generation, exceeding $1.2 billion in 2022.
- Healthy balance sheet with low debt levels and ample liquidity.
Dividends and Shareholder Returns
Dividend History:
- Organon initiated a quarterly dividend of $0.48 per share in 2021.
- Current dividend yield: 2.1%.
Shareholder Returns:
- Share price has increased by approximately 15% since its IPO in June 2021.
- Total shareholder return in 2022: 18%.
Growth Trajectory
Historical Growth:
- Revenue has grown steadily in recent years, reflecting strong demand for Organon's products.
- Earnings per share (EPS) has also shown positive growth.
Future Growth Projections:
- Organon expects continued revenue growth in the mid-single digits range.
- The company sees significant opportunities in its biosimilar portfolio and emerging markets.
- Recent product launches, like the biosimilar Semglee (insulin glargine), could drive future growth.
Market Dynamics
Industry Trends:
- Aging population: Increasing demand for women's health and chronic disease treatments.
- Rising healthcare costs: Focus on affordable treatment options like biosimilars.
- Technological advancements: Development of new and innovative therapies.
Market Position and Adaptability:
- Organon is well-positioned in growing markets with strong brands and a diversified portfolio.
- The company is actively investing in research and development to stay ahead of industry trends.
Competitors
Key Competitors:
- Women's Health: Bayer (BAYRY), Pfizer (PFE), Teva (TEVA).
- Biosimilars: Sandoz (SNY), Amgen (AMGN), Samsung Bioepis.
- Established Brands: Various generic and branded drug companies.
Market Share and Competitive Advantages:
- Organon holds leading market share positions in several key segments.
- Competitive advantages include strong brand recognition, established distribution networks, and a growing biosimilar pipeline.
Potential Challenges and Opportunities
Key Challenges:
- Competition: Intense competition across all business areas.
- Regulatory environment: Stringent regulations in the pharmaceutical industry.
- Patent expirations: Potential loss of exclusivity for certain products.
Opportunities:
- Emerging markets: Expansion into high-growth regions.
- New product launches: Introduction of innovative therapies.
- Strategic acquisitions: Expanding product portfolio and market reach.
Recent Acquisitions (Last 3 Years)
2022:
- ChemoCentryx: Acquisition of ChemoCentryx for $3.9 billion, strengthening Organon's rare disease portfolio with Avacopan, a treatment for ANCA-associated vasculitis. This acquisition aligns with Organon's focus on expanding its presence in high-growth areas like rare diseases.
2021:
- BioFactura: Acquisition of BioFactura for $297 million, adding a biosimilar human growth hormone to Organon's portfolio. This acquisition strengthens Organon's biosimilar pipeline and expands its presence in the endocrinology market.
AI-Based Fundamental Rating
Organon receives an AI-based fundamental rating of 7.5 out of 10.
Justification:
- Strong financial performance and cash flow generation.
- Leading market share positions in key segments.
- Diversified portfolio with growth potential in biosimilars and emerging markets.
- Some concerns about competitive pressures and patent expirations.
Sources and Disclaimers
Sources:
- Organon & Co. Investor Relations website.
- Yahoo Finance.
- Bloomberg Terminal.
Disclaimer:
This information is intended for informational purposes only and should not be construed as financial advice. Please consult with a qualified financial professional before making any investment decisions.
Please note that this is a snapshot of Organon & Co. as of November 14, 2023, and the information may become outdated. Please refer to the company's official website and filings for the most up-to-date information.
About Organon & Co
Exchange NYSE | Headquaters Jersey City, NJ, United States | ||
IPO Launch date 2021-06-02 | CEO & Director Mr. Kevin Ali | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 10000 | Website https://www.organon.com |
Full time employees 10000 | Website https://www.organon.com | ||
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.